Anna Galkin

Company: Axelia Oncology

Job title: CSO

Bio:

Dr. Anna Galkin is the Chief Scientific Officer at Axelia Oncology, where she leads efforts to develop novel immunotherapies that reprogram macrophages for anti-tumor activity. Her work is centered on advancing innovative strategies, such as targeting TLR2, to recalibrate the tumor microenvironment and enhance the efficacy of emerging treatments.

Seminars:

Harnessing TLR2 Agonism to Reprogram Tumor-Associated Myeloid Cells: Insights from Axelia Oncology 12:00 pm

Showcasing Axelia’s approach to shifting immunosuppressive myeloid cells toward a pro-inflammatory, anti-tumor phenotype Sharing key data on pharmacodynamics, immune activation, and tumor microenvironment remodeling Discussing patient stratification strategies and next steps in clinical evaluation of TLR2-based immunotherapyRead more

day: Conference Day Two

Panel Discussion: From Broad Depletion to Targeted Precision: Minimizing Unintended Immune- Consequences 12:30 pm

Examine challenges and mistakes from the past with myeloid depletion strategies and the consequences of non-specific targeting Explore emerging techniques that allow selective modulation of pathogenic myeloid subsets while preserving protective populations Learn how improved targeting can reduce systemic toxicity and improve therapeutic indexRead more

day: Conference Day Two